Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27638993 | 0.79 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL30165065 | 0.79 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL6195448 | 0.78 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL20626849 | 0.78 | PSMD14 (0.36) | TRPV1MEN1KMT2APAX8 | |
| SCHEMBL31555445 | 0.78 | SCN5A (0.49) | TRPV1 | |
| SCHEMBL15323277 | 0.78 | SCN5A (0.49) | TRPV1 | |
| SCHEMBL27639081 | 0.77 | TRPV1 (0.49) | TRPV1MAPK3 | |
| SCHEMBL15624412 | 0.76 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL27638998 | 0.75 | TRPV1 (0.63) | TRPV1 | |
| SCHEMBL20626850 | 0.75 | ALDH1A1 (0.34) | TRPV1MEN1KMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132509-A1 | Substituted Biaryl Analogues | NEUROGEN CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132509-A1 | Substituted Biaryl Analogues | NEUROGEN CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132509-A1 | Substituted Biaryl Analogues | NEUROGEN CORPORATION (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1824839-A2 | SUBSTITUTED BIARYL ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006071538-A2 | SUBSTITUTED BIARYL ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132509-A1 | Substituted Biaryl Analogues | PIGS, PIGO, GPR174 | TRPV1 949/4885MAPK3 2876/4885MEN1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.